Keyword: Dupixent

Sanofi offered a confidential discount as part of a process to secure coverage for Dupixent in the U.K.

Sanofi's CFO search lasted two months and led the company to a financial executive from French automaker PSA Group.

Sanofi's net prices fell 8.4% last year, the drugmaker reported in an update to its pricing policies.

Regeneron needs some Type A newcomers to backstop its aging blockbuster Eylea, but so far, its trio of launches are still seeking traction.

Formulary shutouts were already hurting Sanofi's diabetes numbers. But price cuts and Medicare compounded the pain in the first quarter of 2017.

The cost-effectiveness gatekeeper figures Dupixent works—and offers an option for patients who really need one—but isn't sure it's worth the price.

Psoriasis treatments are getting more effective. But that doesn’t mean patients have easy access to a new-and-improved crop of blockbuster hopefuls.

Sanofi and Regeneron may have had a successful year with Dupixent—approved in March to treat atopic dermatitis—but there's much more to come.

With PCSK9 cholesterol drug Praluent ramping up more slowly than expected, Sanofi and Regeneron plan a new investment in blockbuster hopeful Dupixent.